SOHO 2021 | MANIFEST: pelabresib updates
Prithviraj Bose
• 27 Aug 2021
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer, Houston, TX, talks on updates from the Phase I/II MANIFEST (NCT02158858) trial on pelabresib with and without ruxolitinib for patients with myelofibrosis. Dr Bose shares updated data on the improvements in spleen size, anemia and symptoms. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Prithviraj Bose, MBBS, has received honoraria from Incyte, Celgene, BMS, CTI BioPharma, Sierra Oncology, Novartis, Blueprint Medicines and Kartos; and has received research support from Incyte, Celgene, BMS, CTI BioPharma, Constellation, Kartos, Blueprint Medicines, Astellas, Pfizer, Promedior and NS Pharma.
